The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.
These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies.
In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines Task Forces have developed consensus statements for genitourinary malignancies (renal and prostate carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia). An update of the melanoma consensus statement and new guidelines for bladder and lung cancers are also underway. These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community.
A call for comment period is currently open for SITC members on the consensus statement for the Cancer Immunotherapy Guidelines, bladder cancer. The period opened Tuesday, March 21, with comments due by 5 p.m. ET on Thursday, April 20. Click here to learn more.
Published August 27, 2013 in Nature Reviews Clinical Oncology as "The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma."
An update to the Melanoma guidelines is expected to be published in 2017.
Published November 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."
Published December 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma."
Published December 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia."
SITC follows the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for creating the consensus statement; therefore, each Cancer Immunotherapy Guidelines Task Force comprises a comprehensive mix of academic physicians and researchers,nurses, patients, and patient advocates invited from a diversity of institutions across the United States.
Each expert Task Force addresses knowledge gaps in our understanding of immunotherapy treatments for their disease specialty, and then develops evidence-based recommendations by recording consensus opinions of the Task Force and documenting alternative opinions when they occur.
This may be due to an alternate immune checkpoint, CD200 (OX2) checkpoint blockade. The immuneosuppressive CD200 protein shuts down the immune system through multiple mechanisms (Xiong et al, 2016). We demonstrated that human glioblastoma in the top ...
While I agree with Stephanie's detailed account, simply put checkpoint molecules are a signature of exhausted/ chronically stimulated lymphocytes and therefore serves as a feedback mechanism to mitigate the immune activation from entering an overdrive ...
Hi Stephanie many thanks for your ample reply. It makes sense indeed in order to secure self-antigens. However, is immune system evasion by means of immune checkpoint a matter of quality or quantity? I mean is there a cutoff for "normal"CTLA4, PD1 levels ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org